Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice

The clinical management of H5N1 influenza virus infection in humans remains unclear. Combination chemotherapy with drugs that target different viral proteins might be more effective than monotherapy. BALB/c mice were treated by oral gavage for 5 days with amantadine (1.5, 15 or 30 mg/kg/day) and ose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral therapy 2007-01, Vol.12 (3), p.363-370
Hauptverfasser:	Ilyushina, Natalia A, Hoffmann, Erich, Salomon, Rachelle, Webster, Robert G, Govorkova, Elena A
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Amantadine - administration & dosage Amantadine - pharmacology Amantadine - therapeutic use Animals Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Dose-Response Relationship, Drug Drug Evaluation, Preclinical Drug Resistance, Viral Drug Therapy, Combination Female Influenza A Virus, H5N1 Subtype - drug effects Influenza A Virus, H5N1 Subtype - genetics Mice Mice, Inbred BALB C Microbial Sensitivity Tests Orthomyxoviridae Infections - drug therapy Orthomyxoviridae Infections - virology Oseltamivir - administration & dosage Oseltamivir - pharmacology Oseltamivir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!